RBC Capital Initiates Coverage on Allergan (AGN)
Investment analysts at RBC Capital initiated coverage on shares of Allergan (NYSE:AGN) in a note issued to investors on Tuesday, TheFlyOnTheWall.com reports. The firm set an “outperform” rating and a $131.00 price target on the stock. RBC Capital’s price target points to a potential upside of 16.39% from the company’s current price.
A number of other firms have also recently commented on AGN. Analysts at Zacks upgraded shares of Allergan from a “neutral” rating to an “outperform” rating in a research note to investors on Monday. They now have a $134.00 price target on the stock. Separately, analysts at Credit Suisse set a $123.00 price target on shares of Allergan in a research note to investors on Friday. Finally, analysts at Wells Fargo & Co. upgraded shares of Allergan from a “market perform” rating to an “outperform” rating in a research note to investors on Tuesday, December 24th. Eight investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $113.82.
Allergan (NYSE:AGN) traded up 1.56% on Tuesday, hitting $112.55. The stock had a trading volume of 1,777,169 shares. Allergan has a 1-year low of $81.33 and a 1-year high of $116.45. The stock’s 50-day moving average is $102.0 and its 200-day moving average is $92.90. The company has a market cap of $33.446 billion and a price-to-earnings ratio of 33.59.
Allergan (NYSE:AGN) last released its earnings data on Tuesday, October 29th. The company reported $1.23 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.20 by $0.03. The company had revenue of $1.23 billion for the quarter, compared to the consensus estimate of $1.53 billion. During the same quarter last year, the company posted $1.06 earnings per share. Allergan’s revenue was up 13.3% compared to the same quarter last year. Analysts expect that Allergan will post $4.76 EPS for the current fiscal year.
In other Allergan news, VP Julian Gangolli sold 52,500 shares of Allergan stock in a transaction that occurred on Friday, December 27th. The stock was sold at an average price of $110.05, for a total value of $5,777,625.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
Allergan, Inc, is a multi-specialty health care company focused on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.